Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
Executive Summary
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
You may also be interested in...
Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem
Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer
Keeping Track: A CRL For Tlando, An Accelerated Approval For AndexXa, And A Burst Of Supplemental Approvals
The latest US drug development news and highlights from our Performance Tracker.
Opdivo And Eliquis Carry Bristol’s Q1; Company Continues To Defend IO Strategy
Novel oral anticoagulant Eliquis (apixaban) brought in $1.5bn in the first quarter and is set to overtake warfarin later this year. But Bristol remains on the defense on IO after a disappointing AACR.